Introduction:

The nimotuzumab is a monoclonal antibody used in the treatment of patients with cerebral tumor. The realization of pharmaco surveillance studies that guaranteed its security is justified given its new features.

Objective:

To characterize the adverse events related to this medicine in the habitual medical practice.

Methods:

A descriptive and cross-sectional study of 41 patients with primary cerebral tumor treated with nimotuzumab in the Clinical Trial Department of Saturnino Lora Torres Teaching Provincial Hospital was carried out in Santiago de Cuba, from May, 2017 to April, 2019.

Results:

In the series 31 adverse events were identified, of which 17 were known and 14 were unknown. There was a prevalence of the headache (80.5 %), weakness in lower members (48.8 %) and the high alcaline phosphatase (41.5 %). It is necessary to highlight that all the non wanted effects were considered light according to the intensity; reversible, according to the results and without changes, according to the attitude regarding the medicine.

Conclusions:

The characteristics of the adverse events that were found resemble to those described in other studies that also guarantee the security of the drug.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )